



Tissue Repair Limited Company Update

- ***Progress on TR987[®] Phase 3 trials***
- ***Sales commence for TR Pro+[™]***

September 2023

TR987- Cleared to enter Phase 3 by the FDA. A core Clinical Operations capability has been established with first patient randomisation planned for early Q2 2024



Chronic
wounds

Glucoprime® - Patented platform technology. Applicable to many types of wound healing in humans and animals. Initial focus on products for the treatment of chronic wounds and the aftercare of aesthetic and minor medical procedures.

TR987® cleared for Phase 3. TR987® has the promise of being the first drug approved for venous leg ulcers (VLUs) in 25 years. VLUs represent a significant market with unmet needs.

TR Pro+™ launched June 2023. A novel cosmeceutical that improves skin quality following procedures where the skin may or may not be broken. Aesthetic and minor medical procedures represent a **significant growing market estimated at AUD1b*** market with no clear product leader

* Management estimate

Aesthetic

Key Updates since IPO

- Feedback on the **Phase 3 VLU trial** protocol provided at recent FDA meeting all the key areas of the protocol have been agreed.
- **Chemistry-Manufacturing-Controls and Toxicology programs** have all been accepted by the FDA and are progressing.
- **NEW DATA** A meta-analysis was done on 137 patients from the two Phase 2 VLU trials. Results demonstrated a 60% difference in mean wound area vs placebo (p=0.03). Confirmed a **strong signal of efficacy, providing further confidence to move into Phase 3.**
- **The Company is fully funded** with existing cash resources (+AUD20m) and validated AusIndustry. Overseas Findings Certificates which provide additional significant cash funding estimated to be up to c\$7m over the next 4 years
- **An initial batch of TR Pro+™ was manufactured** for launch in June 2023 supported by 1.5FTE Territory Managers
- Monthly sales growth of 20% per month
- Sold into more than 60 clinics within three months
- Very positive client feedback on healing and skin quality

Despite some delays TR is achieving key milestones . . . within its existing funding envelope



TR987® Phase 3 trial approval received by FDA

- ✓ Glucoprime® API manufactured to meet reference standards – five batches in total (pilot, engineering, and GMP)
- ✓ Successful scale-up of the immunogenic Glucoprime® API has been achieved
- ✓ Glucoprime® API analytical development and characterisation to FDA standard for Phase 3
- ✓ Successful FDA meeting (Type C) provided clarity on CMC and abridged toxicology program
- ✓ **Cleared for Phase 3 (Type B FDA meeting)**
- ✓ Secured Professor Robert Kirsner as the Principal investigator for the Phase 3 trial. Prof Kirsner is eminently experienced and was the PI on a Phase 3 study for the Smith and Nephew VLU drug candidate product

TR Pro+™ Product launch in May 2023

- ✓ Inventory manufactured for launch in June 2023 in Australia with potential for global expansion
- ✓ **Real world evidence study. Compelling patient feedback - 80% rating 4/5 and 5/5 on skin quality and perception of healing**
- ✓ Peer reviewed paper published in Dermatologic Surgery demonstrating a significant improvement in skin quality (wrinkling and elastosis; FDA approved Phase 2 trial)
- ✓ **Attractive gross margins when produced at scale based on expected sale price**
- ✓ Estimates of market size could be c+1b globally. Market wide open no clear category winner
- ✓ In >60 clinics with growth in sales at c20% per month

Intellectual Property

- ✓ First patent published (12 June 2022) to cover manufacturing process (includes 21 years of protection)
- ✓ **Second patent published (23 March 2023) covers use of molecule on any topical skin condition and all forms of healing eg: 21 years of protection for TR987® and TR Pro+™**
- ✓ Regulatory exclusivity maintains for a drug or biologic for 5 years and 12 years, respectively
- ✓ Collaboration established with Prof. Allison Cowin (University of South Australia) on further investigation of the Glucoprime® mechanism of action and a next generation wound healing product utilising Glucoprime®

Funding

- ✓ Founder led ethos to capital management
- ✓ AusIndustry Overseas Findings Certificates confirmed as valid, providing an additional 43.5% R&D rebate on expected expenditure (up to \$7m of additional cash funding)
- ✓ **Fully funded to complete Phase 3 trials and launch TR Pro+™**

TRs technology platform Glucoprime® is applicable for multiple types of wounds in humans and animals

Receptors on macrophages within damaged tissue recognize the Glucoprime® - containing hydrogel. Macrophages are the 'guard' cells that protect against invaders.





Two receptors, Dectin-1 and TLR2, are engaged and trick the body into believing there is a yeast infection. Macrophages become activated to express genes that enable phagocytosis, protein synthesis and cytokine release.



In this way TR987® and TR Pro+™ (with Glucoprime®) initiates a mild innate immune response that attracts more macrophages as well as other immune cells like neutrophils and monocytes.




- In laboratory and clinical studies TR987® and TR Pro+™ have been shown to promote wound healing by activating some genes in macrophages (TNFα and IL-10).
- Macrophages play a key role in re-modelling by releasing growth factors that aid in tissue repair and angiogenesis.
- Current hypothesis suggests that Glucoprime® initiates an initial proinflammatory burst then establishes an extended regenerative phase which allows damaged skin to heal.



The medium term focus is on commercialisation of two products for two discrete applications, each having significant markets and compelling economics

... success in either is a significant value milestone






TR987®
CHRONIC WOUNDS



NEW DATA A recent meta-analysis on 147 patients from two Phase 2 trials has confirmed a strong signal of efficacy and demonstrated a 60% reduction in wound size vs placebo control (p=0.03). A strong data point, providing further confidence on a successful Phase 3 outcome

In March 2023 an individual patient data (IPD) meta-analysis was conducted across the Phase 2A and Phase 2B studies using consistent endpoints adopted in both studies, namely absolute and percent change in ulcer area.

Meta-analysis of all Phase 2 patients
Mean wound reduction change between placebo and active
in VLU 2-12cm² n=147



Meta-analysis of all phase 2 patients. Mean wound reduction change between placebo and active across a range of cohorts . VLU sizes 2-12cm² and 2-20cm²

Population	Dose TR-987 gel	Wound size	Adjusted difference in mean change (95% CL)	p-value
ITT	Low	2-12cmsq	-55.9 (-113.3, 1.52)	0.0562
ITT	Low	All	-31.6 (-68.60, 5.30)	0.0925
PP	Low	2-12cmsq	-58.0 (-103.0, -13.05)	0.0124
PP	Low	All	-41.6 (-72.41, -10.82)	0.0087
ITT	All	2-12cmsq	-60.2 (-114.9, -5.53)	0.0314
ITT	All	All	-33.2 (-65.36, -1.12)	0.0427
PP	All	2-12cmsq	-57.7 (-101.8, -13.47)	0.0114
PP	All	All	-44.3 (-71.16, -17.38)	0.0015

The percent change in ulcer area and actual change in ulcer area (cm²) was analysed using a general linear model with baseline ulcer area and duration of study VLU as covariates. Adjusted treatment effects for TR-987 0.1% gel (low dose) versus placebo and for TR-987 all doses combined (i.e. TR-987 0.1% or 1.0% gel) versus placebo were obtained overall for the ITT and PP populations for all patients from both studies combined and for the subgroup of patients with baseline ulcer area 2-12cm², the proposed inclusion for the planned Phase 3 trials. Results are presented below in tables E2 (percentage change) and E3 (actual change) and graphically in figures E1 (percentage change) and E2 (actual change).





Phase 2B Refresh . . . The Per Protocol cohort in the phase 2B study demonstrated a 20% delta over Standard of Care combined with placebo on a range of metrics. The aim is to replicate this significant clinical effect in a larger patient cohort in a Phase 3 trial

Key Wound Healing Metrics	Adj % Diff Active vs Placebo	Results Active vs Placebo
At least 50% reduction in VLU area	19.1%	OR 4.86 (1.17, 20.2) 89.2% vs 63.1% p=0.030
At least 70% reduction in VLU area	27.0%	OR 3.23 (1.03, 10.1) 74.7% vs 47.7% p=0.044
At least 90% reduction in VLU area	29.6%	OR 3.39 (1.08, 10.6) 65.1% vs 35.5% p=0.036
At least 95% reduction in VLU area	29.3%	OR 3.51 (1.06, 11.6) 55.8% vs 26.5% p=0.039
Achieved 100% re- epithelialized	24.2%	OR 2.82 (0.84, 9.46) 51.5% vs 27.3% p=0.093
Percent change in ulcer area	34.0%	34.0% reduction (-58.7, -9.3), p=0.007

Most clinicians would consider a 10% delta as clinically meaningful TR-987 is demonstrating a clinical affect in phase 2B which is circa 20% . . . double that hurdle

Efficacy signal on percent wound area reduction over the treatment period in Phase 2B study. The per protocol population demonstrated a clear weekly projection towards healing over placebo+SOC



The PP set included all patients which adhered to the protocol and competed the 12 week treatment period and received the full dose over that period

An example of a closed venous leg ulcer following treatment by TR987® during the Phase 2B trial



7.53cm² at screening (Heidelberg Repatriation Hospital Melbourne)
Ulcer present for 208 weeks (4 years prior to enrollment) patient age was 72 with leg ulcers present from age 57



1. Chronic Wounds (Venus Leg Ulcer)
Atypical example of a VLU wound healed with TR-987 2020 Phase IIB Venus Leg Ulcer trial n=67 (2-12cm²)

TR987[®] for chronic wounds - key advantages over current products

**Strong efficacy
signal from well
designed trials**

- No drug or biologic appears to have been approved in chronic wounds since REGRANEX gel in 1997, and as such a drug label with high quality clinical data drives reimbursement and is highly prized
- Strong signal for efficacy in wound healing (including key FDA accepted endpoints) demonstrated in clinical trials

**Aiming to prove
superior in-use
outcomes over
current therapies**

- Existing therapies are expensive and require application by healthcare professionals in a hospital setting. Many are costly as derived from human placental tissue, which is the treatment of choice for chronic wounds in the US
- Tissue Repair aims to provide a superior in-use alternative to these therapies, without reliance on harvesting human tissue and the ease of a topical gel in contrast to a complicated patch or scaffold

**Positive safety
profile**

- TR987[®] has a robust safety profile across its clinical program to date
- TR987[®] has been tested across different indications on over 240 patients with no significant adverse events attributable to the drug product

Ease of use

- Administered topically onto the wound – no complicated bandages or patches
- Can be used in combination with standard of care products, including compression bandaging
- Capable of being administered by a nurse/caregiver or in the home directly by the patient

**Stable over a
long shelf life**

- TR987[®] has preliminary stability testing which suggests a three-to-five-year shelf life at room temperature, with no refrigeration or freezing required

**Having a topical gel as
the delivery mechanism
provides a significant
product in use
advantage over existing
complicated patches
and biologics**





**TR Pro+™ (AESTHETIC AND
MINOR MEDICAL PROCEDURES)**


The Phase 2B study using laser skin resurfacing showed a statistically significant improvement in skin quality at Day 28



Wrinkling

In this group, 85% of responders in the active group achieved a wrinkling score improvement of at least 33% compared to only 50% of responders in the placebo group.


Wrinkling
Proportion of patients with at least 33% improvement at 28 days



Elastosis

In this group, 75% of responders in the active group achieved an elastosis score improvement of at least 33% compared to only 35% of responders in the placebo group.

Elastosis
Proportion of patients with at least 33% improvement at 28 days



Conclusion

TR's recent Phase 2 trial demonstrated that TR Pro+™ generates additional collagen production and fibrosis, filling out wrinkles and fine lines at an accelerated pace.

The Phase 2B study was recently published in a peer reviewed journal
(Wu *et al.* 2022)



Original Article

OPEN

A Novel Macrophage-Activating Gel Improves Healing and Skin Quality After CO₂ Laser Resurfacing of the Chest

Douglas C Wu, MD, PhD, Ramya Kollipara, MD, Marissa J. Carter, PhD, and Mitchel P. Goldman, MD*

BACKGROUND After laser resurfacing, it is imperative that an appropriate postoperative regimen is followed for optimal wound healing. There is currently no consensus about which agents should be used.

OBJECTIVE To evaluate the safety and efficacy of a novel macrophage-activating gel in a Phase 2B trial to be used after fractionated ablative laser resurfacing of the chest.

MATERIALS AND METHODS Forty-two adults who received fractionated CO₂ laser resurfacing of the chest were randomized (active or placebo) for 5 consecutive days after procedure. Skin quality at baseline and follow-up was assessed by a blinded evaluator using the Fitzpatrick–Goldman Wrinkle Scale. Subject satisfaction with skin healing and quality was also assessed.

RESULTS At 28 days according to the Fitzpatrick–Goldman Wrinkle Scale, 85% of subjects achieved an improvement of at least 33% for the active group versus 50% in the placebo group (absolute difference 35%; $p = .04$). Similarly, 75% of subjects achieved an improvement score of at least 33% in elastosis in the active group versus 35% in the placebo group at 28 days (40% absolute difference; $p = .011$).

CONCLUSION This study confirms the potent effects of the novel macrophage-activating gel for optimization of skin healing and quality after laser resurfacing of the chest.

Study Author's concluded “In summary, this study demonstrates the potential of TR Pro+™ 0.1% gel to significantly improve skin quality outcomes after fractionated ablative laser resurfacing without any negative side effects, most likely through a unique immunomodulatory mechanism of action”

A typical example of redness and irritation following treatment by TR Pro+™ in the Phase 2B laser skin resurfacing study

Days post-procedure

Day 1


Day 28



Close to double the improvement in skin quality as measured by elastosis and wrinkling vs standard of care & placebo

In a real-world evidence study (2022), 100% of patients rated TR Pro+™ as good or better than previous post-procedure aftercare product used. . . 85% of patients rated it as 4/5 stars on healing and skin quality

A real-world evidence study⁽¹⁾ with 12 dermatology clinics in Australia in patients (n=48) who had undergone a range of cosmetic and medical procedures. The program was run independently, and patients provided anonymous feedback at day 6 and day 28 following the procedures.



Healthcare professionals who consider TR Pro+™ appealing⁽¹⁾

Dermatologists interested in learning more about the Phase 2 laser skin resurfacing trial⁽²⁾

86%

84%



1 FiftyFive5 TR Pro+ Market Research Dec 2021 (n=57)
2 IQVIA Medibus October 2022 (n=31)

TR Pro+™ - an opportunity to deliver on an unmet need in current therapy following aesthetic and minor medical procedures



Launched in June 2023 (10,000 tubes and sample sachets)

The gel has potential application to a range of cosmetic procedures, including:

- Laser skin resurfacing (particularly ablative)
 - Skin needling
 - IPL treatment
 - Chemical peels
 - Skin cancer removal
 - Biopsy
 - Laser tattoo removal
-
- 1.5 FTE Territory Managers have approached more than 160 clinics since January, with over 60 clinics having placed orders at three months post-launch.
 - Key targets include cosmetic dermatologists, laser technicians, dermal therapists, plastic/cosmetic surgeons
 - The team have global ambitions for TR Pro+™ following a launch in Sydney with learnings to be applied in other geographic markets
 - Additional products under review to develop a portfolio based on the Glucoprime® platform (eg: moisturizer, serum, sunscreen and higher potency aftercare formulation)



The post procedure topical market has no clear product lead, and is potentially a USD1b* market globally

Skincare and cosmetics are significant global markets with strong CAGRs

- Total revenues from the global cosmetics market are set to hit \$103.8 billion in 2023
- Skincare was the leading category accounting for about 41 percent of the global market. Revenue is projected to generate roughly 188 billion U.S. dollars in 2026.

Comparable companies are evidencing revenues of circaUS100m focusing on post procedure repair key call outs across the competitive landscape

- Limited number of products lines revenue concentrated only in a handful of SKU's
- Limited focus on improvement of skin quality more focussed on improved healing (i.e. reduced redness, itching faster healing), and improved scarring
- Existing product lines prohibitively expensive with some products costing in the range of c\$US100-\$US400
- Very limited evidence of efficacy
- No clear product leader or winner with several disparate products recommended by clinicians

Sales Update

- In more than 60 clinics
- Month-on-month sales growth of 20%
- Consistently positive client feedback during first three months in market

TR has an opportunity to create a significant business

- **Focussed on skin quality improvement with a strong data package (underpinned by clinical evidence)**
- **Expand product line - delivering a number of products powered by Glucoprime® with TR Pro+™ as the flagship product**
- **Attractive price points - affording broader adoption**

Regulatory exclusivity
5 years in USA
10 years in Europe

Glucoprime® meets the FDA criteria of A New Chemical Entity (NCE). There is no drug substance currently approved globally for any indication based on Tissue Repair's engineered molecule. This provides the potential for exclusivity preventing competitors from replicating the technology.

- **USA:** The FDA defines a new chemical entity as "a drug that contains no active moiety that has been approved by FDA in any other application submitted under section 505(b) of the Act." The FDA grants exclusivity for New Chemical Entities (NCE). This exclusivity provides the licence holder of an approved new drug application protection from new competition in the marketplace for the innovation represented by its approved drug product.
- **Europe:** A chemical active substance that is not previously authorised in a medicinal product for human use in the European Union and that is from a chemical structure point of view not related to any other authorised substances should be considered as a NAS ("New Active Substance")

If Glucoprime® is classified as a biologic by the FDA, it may be eligible to increase marketing exclusivity from 5 to 12 years in the USA. Whilst the focus for TR987 is as a potential drug approval, the company will also be discussing and considering the classification of Glucoprime® with the FDA as a biologic.

US Divisional Patent Glucoprime **GRANTED**

Methods of manufacture
Pub No US 11,384,160 B1
Publication Date Jul. 12, 2022

METHOD OF MAKING A BETAGLUCAN COMPOUND

- The claims allowed cover the methods of extraction of the Glucoprime® API, there are no other known methods to produce the API to the specifications required by the FDA which link directly to potency and efficacy and in turn clinical impact

US Divisional Patent Glucoprime **GRANTED**

Composition Claims
Pub. No.: US 2023/0085802 A1
Publication Date 23 March 2023

ISOLATED BIOLOGICAL POLYSACCHARIDE COMPOUND, METHODS OF USE AND METHODS OF MANUFACTURE THEREOF


- The claims allowed are relatively broad in terms of the type of skin treatment that may be treated. The only limitation in terms of treatment is that Glucoprime is applied topically to the skin of a wound site. The broadest claim is not restricted in terms of the type of wound and what else the vehicle comprises apart from Glucoprime.

US Divisional Patent Glucoprime **UNDER EXAMINATION**

BIOLOGICAL POLYSACCHARIDE COMPOUND

- The claims sought in this application cover the molecule itself for any application

Tissue Repair. Strategy on a Page



Capital Structure Update

Shares on Issue	60,464,843		
Options on issue	22,270,580	\$ 0.49	(Average exercise price)
Cash as at 31 March 2023	\$21.8m		
Cash backing per share	\$0.36		
Share price as	\$0.28		
Market Capitalisation	\$17m		
Discount to cash backing	c-25%		

All seed and founders escrowed for up to 3 years to align with Phase 3 readout

All options issued pre IPO, did not dilute IPO shareholders

Majority founder and management team held, (significant portion has not vested), all options subject to log dated escrow

Cash back excludes significant estimated R&D rebates from pre-approved R&D certificates with AusIndustry



Appendix
Additional clinical data -
Phase 2B Trial

Phase 2B ITT Summary Results.

Partial and complete healing metrics.

Table 15 Summary of key efficacy findings: ITT population

Subset	Treatment	VLU area reduction by week 12 [a,b,c]	At least 50% reduction in VLU area [c,d,e]	At least 70% reduction in VLU area [c,d,e]	At least 90% reduction in VLU area [c,d,e]	At least 95% reduction in VLU area [c,d,e]	VLU healed by week 12 [d,e,f]
Baseline VLU 2-20cm ²	Placebo	-29.8%	46.4%	36.2%	26.5%	19.4%	20.7%
	TR 987 0.1% gel	-42.3%	66.6%	56.7%	47.5%	40.6%	37.1%
	Difference	12.5%	20.2%	20.5%	20.9%	21.2%	16.4%
	(95% CL)	(-17.0%, 41.9%)	(-1.4%, 40.2%)	(-1.3%, 40.4%)	(-0.2%, 40.1%)	(1.0%, 39.5%)	(-3.6%, 35.0%)
	Odds ratio		2.3	2.31	2.5	2.84	2.26
	(95% CL)		(0.87, 6.12)	(0.89, 5.98)	(0.92, 6.82)	(0.96, 8.34)	(0.78, 6.57)
	p-value		0.094	0.085	0.073	0.058	0.134
Baseline VLU 2-12cm ²	Placebo	-30.5%	52.1%	40.7%	31.4%	26.5%	27.9%
	TR 987 0.1% gel	-48.3%	74.7%	64.8%	57.1%	49.3%	48.3%
	Difference	17.8%	22.6%	24.1%	25.7%	22.8%	20.4%
	(95% CL)	(-19.1%, 54.7%)	(-0.7%, 44.2%)	(-0.2%, 45.8%)	(1.4%, 47.0%)	(-1.0%, 43.9%)	(-3.4%, 41.8%)
	Odds ratio		2.72	2.68	2.91	2.7	2.42
	(95% CL)		(0.86, 8.64)	(0.85, 8.52)	(0.91, 9.26)	(0.83, 8.80)	(0.77, 7.58)
	p-value		0.09	0.094	0.071	0.1	0.13
Baseline VLU 2-7cm ²	Placebo	-25.4%	47.7%	31.7%	27.9%	25.0%	34.4%
	TR 987 0.1% gel	-35.4%	70.1%	62.3%	57.0%	50.7%	49.1%
	Difference	10.0%	22.4%	30.5%	29.1%	25.7%	14.7%
	(95% CL)	(-37.2%, 57.2%)	(-5.9%, 46.9%)	(2.1%, 54.5%)	(1.0%, 53.4%)	(-1.8%, 50.3%)	(-13.0%, 40.8%)
	Odds ratio		2.57	3.55	3.42	3.08	1.84
	(95% CL)		(0.71, 9.30)	(0.94, 13.3)	(0.89, 13.2)	(0.81, 11.8)	(0.55, 6.19)
	p-value		0.15	0.061	0.074	0.1	0.325

LOCF, last observation carried forward.

[a] Adjusted difference in ulcer area reduction and adjusted odds ratio estimates obtained from repeated measures mixed model with percentage change in area as outcome, and treatment group, treatment visit (and interaction), and baseline VLU area as explanatory variables

[b] For testing the null hypothesis that the difference in percentage change in VLU area between the treatment groups is zero

[c] Subjects are classified at Week 12 using LOCF values if no data is recorded at Week 12

[d] Adjusted difference in healing rates and adjusted odds ratio obtained from the logistic model with baseline covariates for age at time of VLU, duration of study VLU, and baseline VLU area

[e] p-value for testing the null hypothesis that the adjusted odds ratio equals 1

[f] Subjects are classified as healed if there is 100% re-epithelialization of the study VLU with no drainage noted. This must be confirmed at a subsequent study visit.

Phase 2B Per Protocol Summary Results.

Partial and complete healing metrics.



CLINICAL STUDY REPORT
TR Therapeutics, Inc.

CONFIDENTIAL
Protocol No: BG001

Table 16 Summary of key efficacy findings: PP population

Subset	Treatment	VLU area reduction by week 12 [a,b,c]	At least 50% reduction in VLU area [c,d,e]	At least 70% reduction in VLU area [c,d,e]	At least 90% reduction in VLU area [c,d,e]	At least 95% reduction in VLU area [c,d,e]	VLU healed by week 12 [d,e,f]
Baseline VLU 2-20cm ²	Placebo	-41.8%	63.1%	47.7%	35.5%	26.5%	27.3%
	TR 987 0.1% gel	-75.8%	89.2%	74.7%	65.1%	55.8%	51.5%
	Difference	34.0%	26.2%	27.0%	29.6%	29.4%	24.2%
	(95% CL)	(9.3%, 58.7%)	(5.2%, 46.2%)	(2.6%, 48.6%)	(4.5%, 51.2%)	(4.7%, 50.6%)	(-0.4%, 46.0%)
	Odds ratio		4.86	3.23	3.39	3.51	2.82
	(95% CL)		(1.17, 20.2)	(1.03, 10.1)	(1.08, 10.6)	(1.06, 11.6)	(0.84, 9.46)
	p-value		0.03	0.044	0.036	0.039	0.093
Baseline VLU 2-12cm ²	Placebo	-43.8%	69.4%	57.8%	45.4%	38.3%	38.2%
	TR 987 0.1% gel	-88.5%	97.1%	86.3%	77.1%	66.7%	66.3%
	Difference	44.7%	27.7%	28.5%	31.7%	28.4%	28.1%
	(95% CL)	(15.1%, 74.4%)	(8.2%, 49.0%)	(3.5%, 51.5%)	(4.2%, 55.1%)	(0.1%, 52.5%)	(-0.2%, 52.3%)
	Odds ratio		14.8	4.62	4.04	3.23	3.18
	(95% CL)		(1.38, 159)	(1.03, 20.7)	(1.05, 15.5)	(0.87, 12.0)	(0.85, 11.9)
	p-value		0.026	0.046	0.042	0.08	0.087
Baseline VLU 2-7cm ²	Placebo	-37.8%	66.5%	46.6%	41.8%	37.2%	47.1%
	TR 987 0.1% gel	-88.0%	95.8%	84.1%	78.0%	69.3%	67.4%
	Difference	50.3%	29.3%	37.6%	36.2%	32.1%	20.3%
	(95% CL)	(11.3%, 89.2%)	(2.3%, 52.1%)	(5.3%, 61.9%)	(3.0%, 61.5%)	(-1.5%, 58.9%)	(-12.9%, 48.8%)
	Odds ratio		11.5	6.09	4.94	3.81	2.32
	(95% CL)	(11.3%, 89.2%)	(0.90, 147)	(1.11, 33.5)	(0.95, 25.7)	(0.82, 17.7)	(0.57, 9.51)
	p-value		0.061	0.038	0.057	0.087	0.241

LOCF, last observation carried forward.

[a] Adjusted difference in ulcer area reduction and adjusted odds ratio estimates obtained from repeated measures mixed model with percentage change in area as outcome, and treatment group, treatment visit (and interaction), and baseline VLU area as explanatory variables


[b] For testing the null hypothesis that the difference in percentage change in VLU area between the treatment groups is zero

[c] Subjects are classified at Week 12 using LOCF values if no data is recorded at Week 12

[d] Adjusted difference in healing rates and adjusted odds ratio obtained from the logistic model with baseline covariates for age at time of VLU, duration of study VLU, and baseline VLU area

[e] p-value for testing the null hypothesis that the adjusted odds ratio equals 1

[f] Subjects are classified as healed if there is 100% re-epithelialization of the study VLU with no drainage noted. This must be confirmed at a subsequent study visit.



Important notice and disclaimer

This presentation (Presentation) is dated 18/09/2023 and has been prepared by Tissue Repair Ltd (ACN 158 411 566) (Tissue Repair or the Company).

Information in this Presentation

The information in this Presentation is of a general background nature for informational purposes, is in summary form and does not purport to be complete. It does not contain all information relevant or necessary for an investment decision or that would be required to be included in a prospectus or other disclosure document under the *Corporations Act 2001*(Cth) (Corporations Act) for an offer of securities in Australia or in any other jurisdiction. The content of this Presentation is provided as at the date of this Presentation (unless otherwise stated). The information in this Presentation is subject to change without notice and, subject only to any legal obligation to do so. The Company does not have any obligation to correct or update the content of this Presentation.

Not a prospectus or offer of securities

This Presentation is not a prospectus or any other offering document under Australian law and will not be lodged with the Australian Securities Investments Commission (ASIC). This Presentation is not, and does not constitute, an invitation, offer or recommendation of securities for subscription, purchase or sale in any jurisdiction. This Presentation also does not form the basis of any contract or commitment to issue, sell or apply for securities in Tissue Repair or any of its subsidiaries.

Past and future performance

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This Presentation contains certain forward-looking statements with respect to the financial condition, operations and business of the Company and certain plans and objectives of the Company. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms “believes”, “estimates”, “anticipates”, “expects”, “predicts”, “intends”, “plans”, “targets”, “aims”, “outlook”, “guidance”, “forecasts”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. These forward looking statements involve known and unknown risks, uncertainties and other factors that because of their nature may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward looking statements. They are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which the Company will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, the Company disclaims any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Restriction on distribution

The distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. Any recipient of this Presentation who is outside Australia must seek advice on and observe any such restrictions.

Not financial or product advice

Reliance should not be placed on the information or opinions contained in this Presentation. This presentation is for informational purposes only and is not financial product or investment advice or recommendation to acquire any securities in the Company and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Nothing contained in this Presentation constitutes investment, legal, tax or other advice. An investor is solely responsible for forming its own opinions and conclusions on such matters and the market and for making its own independent assessment of the information provided. Any investment decision should be made solely on the basis of the investor’s own enquiries and it should consider whether such an investment is appropriate to its particular investment objectives, financial situation and needs.

Recipients should conduct their own research into the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this Presentation. Recipients should seek legal, financial, tax and other advice appropriate to your jurisdiction. Tissue Repair is not licensed to provide financial product advice. An investment in securities is subject to known and unknown risks, some of which are beyond the control of Tissue Repair and its directors, including, possible loss of income and principal invested. Tissue Repair does not warrant or represent that the information in this Presentation is free from errors, omissions or misrepresentations or is suitable for an investor’s intended use. Subject to any terms implied by law and which cannot be excluded, Tissue Repair accepts no responsibility for any loss, damage, cost or expense (whether direct, or indirect, consequential, exceptional or special damages including but not limited to loss of revenue, profits, time, goodwill, data, anticipated savings, opportunity, business reputation, future reputation, production or profit, any delay costs, economic loss or damage) incurred by an investor as a result of any error, omission or misrepresentation in this Presentation. Tissue Repair does not guarantee any particular rate of return or the performance of the Company, nor does it guarantee any particular tax treatment.

Financial information

The Financial Information has been prepared in accordance with the recognition and measurement principles prescribed by the Generally Accepted Accounting Principles in Australia which complies with the International Financial Reporting Standards (IFRS). The Financial Information is presented in an abbreviated form. It does not include all of the presentation and disclosures required by the IFRS and other mandatory professional reporting requirements applicable to general purpose financial reports prepared in accordance with the Corporations Act or Australian law. All financial amounts contained in this Presentation are expressed in Australian currency, unless otherwise stated. Any discrepancies between totals and sums of components in tables contained in this Presentation are due to rounding.

Third party information and market data

The views expressed in this Presentation may contain information that has been derived from independent third party reports, research, clinical papers, surveys or publicly available sources that have not been independently verified by Tissue Repair or its advisers. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Acceptance

By attending a presentation or briefing, or accepting, accessing or reviewing this Presentation you acknowledge and agree to the terms set out in this section of the Presentation titled ‘Important notice and disclaimer’. This Presentation may not be copied, disseminated, distributed, quoted, referred to or otherwise reproduced or published, in whole or in part, for any purpose without the prior written permission of Tissue Repair.

